What Cathflo Treats: Main Uses and Benefits

Cathflo is used for managing acute functional failure of a central venous access device (CVAD). Its application is focused on localized access issues that interfere with patient care.

The medication is utilized for the restoration of function to central venous access devices. This application is relevant for the loss of catheter patency linked to thrombotic obstruction. Cathflo is used to address symptoms such as the complete inability to withdraw blood or noticeably sluggish flow during infusion.

Therapeutic Focus and Benefit

These symptoms may occur across various clinical scenarios, including maintaining access for long-term chemotherapy, antibiotics, or hemodialysis. The primary therapeutic application provides support by assisting with the localized management of the obstruction. The intervention is intended to help preserve the patient’s existing venous access, which supports the continuity of care. The use of Cathflo assists with maintaining the usability of the central line for both adults and pediatric patients requiring continuous treatments.

Quick Fact: Support for Functional Symptoms
Cathflo is used to help manage symptoms that interfere with daily functioning, supporting comfort during periods of heightened physical stress.

Who Can and Cannot Use Cathflo (Alteplase)?

Official eligibility rules for Cathflo are determined by regulatory authorities and focus on patient age, weight, and pre-existing medical conditions, particularly those that increase bleeding risk.

---

Approved Populations and Restrictions

Cathflo is approved for use in both adults and pediatric patients for restoring function to a thrombotic-occluded central venous access device. Clinical trials for the pediatric population included patients as young as 2 weeks of age, but regulatory data is not established for patients who weigh less than 10 kg.

Contraindications and Conditional Use

Cathflo must not be used (is contraindicated) in patients with a known hypersensitivity to alteplase or any other component of the formulation. It is also prohibited for patients who have active internal bleeding or have undergone recent major surgery or percutaneous puncture of a non-compressible vessel within the preceding 48 hours.

Use is considered conditional or requires caution for patients with severe hepatic or renal disease that may cause hemostatic defects, or if there is a suspected infection in the catheter itself.

Regarding reproductive status, there are no adequate and well-controlled studies in pregnant women, and its use must be determined by a risk-benefit assessment. It is unknown whether alteplase is excreted in human milk, and a decision on discontinuing breastfeeding may be required.

Interactions with other medicines and products

Official regulatory information for Cathflo (Alteplase, 2 mg) confirms that formal drug-drug interaction studies have not been performed for its use in restoring function to central venous access devices. Consequently, the interaction profile is defined by expected pharmacological effects and procedural constraints noted in regulatory documents.

Documented Pharmacodynamic Risks

Co-administration with certain substance categories increases the risk of a serious outcome, primarily due to combined effects on the blood system.

• Drugs affecting Coagulation and Platelet Function: The combined use of Cathflo with agents such as oral anticoagulants, platelet aggregation inhibitors, unfractionated heparin, and low molecular weight heparin (LMWH) increases the risk of haemorrhage or bleeding. This additive risk is noted in prescribing information.
• Angiotensin-Converting Enzyme (ACE) Inhibitors: Concomitant treatment with ACE inhibitors may enhance the risk of suffering a hypersensitivity reaction, such as angioedema.

Administration and Timing Restrictions

The regulatory label establishes strict procedural rules regarding co-administration:

• Co-instillation is not recommended: Cathflo should never be co-instilled or mixed with any other medication, including heparin. If heparin is required to prevent re-occlusion, it must be administered separately only after the function of the central venous access device has been restored.

No specific interactions with food, alcohol, or herbal products are documented in the official prescribing information.

The mechanism of Cathflo focuses exclusively on the highly targeted, localized dissolution of the fibrin component of a clot obstructing a central venous access device (CVAD). It utilizes the body's natural clot-breaking processes but accelerates and concentrates them directly at the site of the blockage.

---

Targeted Fibrin Binding and Activation

This domain describes the initial molecular step: the drug, a recombinant tissue plasminogen activator (t-PA), acts as an enzyme to bind selectively to fibrin within the thrombus. This binding initiates the local conversion of the inactive molecule plasminogen into the active enzyme plasmin, localizing its enzymatic activity.

---

️ Acceleration of the Fibrinolytic Cascade

The fibrinolytic cascade is the key pathway affected, driven by the newly generated plasmin. This active enzyme then catalyzes the breakdown of the fibrin meshwork, a process known as fibrinolysis. The resulting physiological effect is the physical dissolution of the thrombus, which enables flow patency.

---

Mechanistic Specificity and Constraints

This action is defined by its thrombus-specificity, meaning the drug's mechanism is physiologically limited to dissolving fibrin-based occlusions. The localized application constrains the action primarily to the target site, resulting in limited systemic circulation exposure and preventing generalized fibrinogen degradation.

How to Use Cathflo: Administration Guidelines

Cathflo (Alteplase) is prescribed for the restoration of function to central venous access devices (CVADs) that have become occluded by a clot. Its use follows a specific protocol for localized administration, distinct from how Alteplase may be used for other systemic conditions.

---

Administration Scope

Feature	Guidelines
Route of administration	Intracatheter instillation (directly into the occluded catheter lumen).
Standard Dosing Schedule	Standard Dose (ge 30 kg): 2 mg in 2 mL. A single second 2 mg dose may be instilled if function is not restored after the first dose's total dwell time.
Age-group rules	Pediatric Patients < 30 kg: The dose is 110% of the catheter’s internal lumen volume, not to exceed 2 mg.

---

Procedural Requirements

Administration involves specific steps beginning with preparation. The drug is supplied as a powder and is reconstituted to a concentration of 1 mg/mL using Sterile Water for Injection, USP, with gentle swirling; shaking is avoided.

Dwell Time and Removal: The solution is typically left in the catheter for a 30-minute initial dwell time, followed by up to 120 minutes total if needed. Following the attempt to restore function, the drug, fluid, and residual clot are aspirated and discarded. The line is then flushed with 0.9% Sodium Chloride solution to complete the procedure. Excessive pressure is avoided during instillation.

Research Evidence / Overview of Studies for Cathflo

The research on Cathflo (alteplase) has been structured to explore its use in two main areas: Catheter Management and Systemic Thrombolysis. This overview describes the types of studies conducted, the observations reported by researchers, and the areas where information remains insufficient or uncertain.

Evidence for use in Catheter Management

The drug was studied for use in conditions marked by functional limitations related to catheter performance. Research exploring these outcomes has primarily relied on short-term randomized controlled trials (RCTs). These trials typically examined specific patient groups, and studies monitored changes over short intervals. Outcomes were related to functional status and patency measures.

Findings describe patterns observed in the studies regarding how patency measures evolved in the observed populations. Some trials described how functional interference was reported compared to the start of the study. However, the reported outcomes were generally short-term, meaning that research provides insight into short-term changes but long-term effects are not fully established. Evidence for this indication is limited and heterogeneous across the trials that were conducted.

Evidence for use in Systemic Thrombolysis

For systemic conditions, which are associated with outcomes related to systemic or functional imbalance, the drug was evaluated in a set of research, including large, parallel-group randomized controlled trials and real-world evidence (RWE) studies. Researchers examined outcomes related to functional recovery and physiological status, and also monitored outcomes linked to severe vascular events over defined time intervals.

The large trials monitored how functional scores changed in the observed populations over intermediate follow-up periods. Large cardiovascular studies, which extended up to 5 years, monitored the occurrence of major vascular events and reported those measurements. These studies report how symptoms evolved in the observed populations and findings describe patterns observed in the studies regarding physiological parameters.

Long-term studies and follow-up

For both indications, research explored short-term changes, but limited information for long-term outcomes is uniformly established. In Catheter Management, most findings describe patterns observed during follow-up durations that were limited to a few months. For Systemic Thrombolysis, cardiovascular outcomes trials provided the most extended follow-up, contributing to the broader evidence landscape regarding long-term outcomes related to systemic or functional imbalance.

Evidence in special populations

Specific subgroups were evaluated in the research, such as adults with pre-existing vascular disease or specific comorbidities. Findings for these specific cohorts were observed in some studies. However, data for certain groups remain insufficient. For instance, there is limited information for individuals at the extreme ends of the age spectrum. Specifically, data are still emerging, and there is a lack of information for pediatric or adolescent populations for both conditions.

What is still uncertain about Cathflo

Overall, the evidence highlights what is known—and what is still uncertain. For the Catheter Management indication, certainty remains low due to modest sample sizes and follow-up durations that were limited. For the Systemic Thrombolysis indication, while the data contribute to the broader evidence landscape for vascular event tracking, results apply only to the populations studied, and comparative evidence is lacking. Research is ongoing to explore these remaining gaps.

Key Studies & References

1. Alteplase - StatPearls (Source of consolidated indications, mechanisms, and safety warnings)

Common questions about Cathflo (FAQ)

Q: What is Cathflo (alteplase) used for?

A: According to the official product information, Cathflo (alteplase) is used to restore function to central venous access devices (CVADs) that have become blocked by a blood clot. This is necessary when the CVAD is needed for drawing blood or giving fluids and medicines, but the blockage is preventing its proper use.

Q: How does Cathflo work to clear a blocked catheter?

A: Regulatory documents state that Cathflo contains the active substance alteplase, which is a thrombolytic agent, or 'clot buster.' It works by activating a natural process in the body to break down the specific clot, which is called a 'thrombus,' that is blocking the central venous access device.

Q: Is Cathflo different from the alteplase used for heart attacks or strokes?

A: While Cathflo and the alteplase used for other conditions, such as heart attack or stroke, contain the same active ingredient, Cathflo is approved and labeled specifically for restoring function to blocked central venous access devices. The official product information specifies its use and administration for this particular purpose.

Q: How long does it take for Cathflo to clear the blockage?

A: The official product information indicates the recommended process involves waiting for a certain period of time after Cathflo is instilled into the catheter. After this designated dwell time, the catheter function is checked to assess if the blockage has been cleared, as outlined in the prescribing information.

Q: What is a central venous access device (CVAD)?

A: According to the context provided in the official materials for Cathflo, a CVAD is a catheter placed in a large vein that allows medical staff to draw blood or give fluids, medicines, or nutrition. Examples include tunneled catheters, non-tunneled catheters, and implanted ports, all of which can be prone to blockages.

Q: What happens if the catheter is still blocked after the first treatment?

A: Official information indicates that if the central venous access device remains blocked after the first attempt, a repeat dose may be considered by the healthcare professional. This second treatment follows the same steps, including instilling the medicine and waiting for the designated period before checking the catheter's function again.

Q: Is Cathflo the only way to treat a blocked catheter?

A: Studies and official information indicate that Cathflo is approved specifically for restoring function to catheters that are blocked due to a blood clot, or thrombotic occlusion. The product information specifies that a diagnosis of thrombotic occlusion is necessary before its use is considered.

How to Store and Dispose of Cathflo Activase (Alteplase)

Storage Conditions

The unopened vial containing the lyophilized powder of Cathflo Activase must be stored under refrigeration, specifically between 2 C and 8 C (36 F and 46 F). The powder should be protected from excessive exposure to light during extended storage. The medication must not be used beyond its expiration date.

Stability and Handling

The product contains no antibacterial preservatives and should be reconstituted immediately before use using aseptic technique. After mixing, the solution is stable for up to 8 hours when stored between 2 C and 30 C (36 F and 86 F). No other medication should be added to the solution.

Disposal Requirements

Any unused portion of the reconstituted solution must be discarded. Disposal of unused or expired Cathflo Activase and related materials must comply with institutional procedures and local regulations for safe pharmaceutical waste handling. The medicine must be kept out of the sight and reach of children.